IMRX vs PSA · $124.2M cap vs rev $4.82B
Immuneering Corp (IMRX) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
IMRX currently screens at market cap $124.2M. PSA currently screens at market cap $0.
Not investment advice. Open the IMRX and PSA stock pages for the full models.
Not investment advice.